OABI logo

OABI OmniAb, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$4.66
-0.37 (-7.36%)

OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capabilit…

Market Cap: $679.71Mwww.omniab.com

Price

No data yet.

Social Signal Score

51
5d
—
30d
49
6 mentions
—
60d
53
9 mentions
—
90d
53
9 mentions
—
news: 9

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 0Sell 0Strong Sell 0
Avg price target$4-14.2%
Low $4Median $4High $4
Current Consensus

Revenue

$3.99M-19.93%
$2.24M$13.27M$24.31M$35.34M
Sep 2020Sep 2026

Analyst Estimates

FY2025
$-0.54
$-0.57–$-0.51
4 analysts
FY2026
$-0.31
$-0.34–$-0.28
4 analysts
FY2027
$-0.22
$-0.24–$-0.20
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Matthew W. Foehr
Sector
Healthcare
Industry
Biotechnology
Employees
89
Beta
1.05
Country
US
Piotroski score
4 / 9 (Middling)
Altman Z-score
8.68
www.omniab.com